MedTrace Logo

Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab

NCT01213238 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2019-03-15

No results posted yet for this study

Summary

The goal of this clinical research study is to find the highest tolerable dose of the combination of oxaliplatin and capecitabine with or without bevacizumab that can be given to patients with advanced cancer that has spread to the liver. The safety of these drug combinations will also be studied.

Conditions

Interventions

DRUG

Oxaliplatin

140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle.

DRUG

Capecitabine

Starting dose of 500 mg/m2 by mouth twice daily, on days 1 - 14 of a 21 day cycle.

DRUG

Bevacizumab

10 mg/kg by vein on day 1 of a 21 day cycle.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Apostolia M. Tsimberidou, MD, PHD · M.D. Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2018-09-26
Completion
2018-09-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01213238 on ClinicalTrials.gov